Henry Withers of Roswell Park Cancer Institute, Department of Genetics discusses how the data can predict which patients are at risk for metastatic disease and his hopes for a potential biomarker that can be used to identify patients with aggressive prostate cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.